Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Innovative approaches to optimizing the delivery of vancomycin in individual patients.

Pai MP, Neely M, Rodvold KA, Lodise TP.

Adv Drug Deliv Rev. 2014 Nov 20;77:50-7. doi: 10.1016/j.addr.2014.05.016. Review.

2.

Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.

Frymoyer A, Guglielmo BJ, Hersh AL.

Pediatr Infect Dis J. 2013 Oct;32(10):1077-9. doi: 10.1097/INF.0b013e318299f75c.

PMID:
23652479
3.

Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?

Patel K, Crumby AS, Maples HD.

Paediatr Drugs. 2015 Apr;17(2):97-103. doi: 10.1007/s40272-015-0117-5.

PMID:
25644329
4.

Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?

Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, McNutt LA.

Clin Infect Dis. 2014 Sep 1;59(5):666-75. doi: 10.1093/cid/ciu398.

PMID:
24867791
5.

Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.

Jung Y, Song KH, Cho Je, Kim HS, Kim NH, Kim TS, Choe PG, Chung JY, Park WB, Bang JH, Kim ES, Park KU, Park SW, Kim HB, Kim NJ, Oh MD.

Int J Antimicrob Agents. 2014 Feb;43(2):179-83. doi: 10.1016/j.ijantimicag.2013.10.017.

PMID:
24315788
6.
7.

[Therapeutic monitoring of vancomycin in routine clinical practice].

Kacířová I, Grundmann M.

Vnitr Lek. 2014 Oct;60(10):846-51. Review. Czech.

PMID:
25382007
8.

Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.

Lim HS, Chong YP, Noh YH, Jung JA, Kim YS.

J Clin Pharm Ther. 2014 Apr;39(2):196-203. doi: 10.1111/jcpt.12123.

PMID:
24428720
9.

Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.

Ploessl C, White C, Manasco K.

Pediatr Infect Dis J. 2015 Oct;34(10):e244-7. doi: 10.1097/INF.0000000000000817.

PMID:
26121203
11.

Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.

Adane ED, Herald M, Koura F.

Pharmacotherapy. 2015 Feb;35(2):127-39. doi: 10.1002/phar.1531.

PMID:
25644478
12.

The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.

Waineo MF, Kuhn TC, Brown DL.

J Clin Pharm Ther. 2015 Jun;40(3):259-65. doi: 10.1111/jcpt.12270. Review.

PMID:
25865426
13.

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A.

Arch Intern Med. 2006 Oct 23;166(19):2138-44.

PMID:
17060545
14.

Use of Monte Carlo simulation to evaluate the development of vancomycin resistance in meticillin-resistant Staphylococcus aureus.

Mei Q, Ye Y, Zhu YL, Cheng J, Yang HF, Liu YY, Li HR, Li JB.

Int J Antimicrob Agents. 2015 Jun;45(6):652-6. doi: 10.1016/j.ijantimicag.2015.01.018.

PMID:
25813394
15.

Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients.

Silva DC, Seixas GT, Araujo OR, Arduini RG, Carlesse FA, Petrilli AS.

Braz J Infect Dis. 2012 Jul-Aug;16(4):361-5. doi: 10.1016/j.bjid.2012.06.011.

16.

Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.

Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Warren SJ, Gao W, Howden BP, Johnson PD.

Antimicrob Agents Chemother. 2013 Apr;57(4):1654-63. doi: 10.1128/AAC.01485-12.

17.

Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Giuliano C, Haase KK, Hall R.

Expert Rev Anti Infect Ther. 2010 Jan;8(1):95-106. doi: 10.1586/eri.09.123. Review. Erratum in: Expert Rev Anti Infect Ther. 2010 Feb;8(2):250. Giulano, Christopher [corrected to Giuliano, Christopher].

18.

Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.

Frymoyer A, Hersh AL, Coralic Z, Benet LZ, Joseph Guglielmo B.

Clin Ther. 2010 Mar;32(3):534-42. doi: 10.1016/j.clinthera.2010.03.005.

19.

Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.

Nicasio AM, Bulitta JB, Lodise TP, D'Hondt RE, Kulawy R, Louie A, Drusano GL.

Antimicrob Agents Chemother. 2012 Feb;56(2):682-6. doi: 10.1128/AAC.05664-11.

20.

Association between vancomycin trough concentration and area under the concentration-time curve in neonates.

Frymoyer A, Hersh AL, El-Komy MH, Gaskari S, Su F, Drover DR, Van Meurs K.

Antimicrob Agents Chemother. 2014 Nov;58(11):6454-61. doi: 10.1128/AAC.03620-14.

Supplemental Content

Support Center